We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Uptake of 4-borono-2-[<sup>18</sup>F]fluoro- L-phenylalanine in sporadic and neurofibromatosis 2-related schwannoma and meningioma studied with PET.
- Authors
Havu-Aurén, Katja; Kiiski, Johanna; Lehtiö, Kaisa; Eskola, Olli; Kulvik, Martti; Vuorinen, Ville; Oikonen, Vesa; Vähätalo, Jyrki; Jääskeläinen, Juha; Minn, Heikki
- Abstract
Meningiomas and schwannomas associated with neurofibromatosis 2 (NF2) are difficult to control by microsurgery and stereotactic radiotherapy alone. Boron neutron capture therapy (BNCT) is a chemically targeted form of radiotherapy requiring increased concentration of boron-10 in tumour tissue. PET with the boron carrier 4-borono-2-[18F]fluoro- L-phenylalanine ([18F]FBPA) allows investigation of whether 4-borono- L-phenylalanine (BPA) concentrates in NF2 tumours, which would make BNCT feasible. We studied dynamic uptake of [18F]FBPA in intracranial meningiomas ( n=4) and schwannomas ( n=6) of five sporadic and five NF2 patients. Tracer input function and cerebral blood volume were measured. [18F]FBPA uptake in tumour and brain was assessed with a three-compartmental model and graphical analysis. These, together with standardised uptake values (SUVs), were used to define tumour-to-brain [18F]FBPA tissue activity gradients. Model fits with three parameters K 1 (transport), k 2 (reverse transport) and k 3 (intracellular metabolism) were found to best illustrate [18F]FBPA uptake kinetics. Maximum SUV was two- to fourfold higher in tumour as compared with normal brain and independent of NF2 status. The increased uptake was due to higher transport of [18F]FBPA in tumour. In multiple-time graphical analysis (MTGA, Gjedde-Patlak plot) the tumour-to-brain [18F]FBPA influx constant ( K i -MTGA) ratios varied between 1.8 and 5.4 in NF2-associated tumours while in sporadic tumours the ratio was 1–1.4. [18F]FBPA PET offers a viable means to evaluate BPA uptake in meningiomas and schwannomas in NF2. Based on our results on tumour uptake of [18F]FBPA, some of these benign neoplasms may be amenable to BNCT.
- Subjects
BORON-neutron capture therapy; NEUROFIBROMATOSIS; THERAPEUTIC use of boron isotopes; MENINGIOMA; BRAIN tumors; POSITRON emission tomography; CANCER radiotherapy; RADIOACTIVE tracers in biochemistry; DIAGNOSIS
- Publication
European Journal of Nuclear Medicine & Molecular Imaging, 2007, Vol 34, Issue 1, p87
- ISSN
1619-7070
- Publication type
Article
- DOI
10.1007/s00259-006-0154-y